Breaking News on Drug Discovery |
All news articles > December 2005
| « Previous month | Next month » |
22-Dec-2005
Thermo unveils LIMS for lab-based analysis
Thermo Electron has unveiled its latest Laboratory Information Management System (LIMS), its latest evolution in commercial-off-the-shelf (COTS) laboratory information management systems for pharmaceutical manufacturing R&D and QA/QC.
Wyeth opens Dublin drug discovery research facility
Wyeth are to establish a Bio-therapeutic Drug Discovery Research Facility in Dublin in a move that adds to Wyeth Grange Castle Campus in Ireland's capital and reinforces the growth of Ireland's biotechnology research and industrial base.
New array sequences mitochondrial genome quicker
Affymetrix has launched its latest microarray sequencer, which enables researchers to identify genetic variations associated with diseases, forensics, population studies or stem cells, proving particularly useful in drug research and development.
BioGenetics Capital invests $5.5M in Clinquest Group
BioGenetics Capital announced that it has closed a $5.5 million financing round with Contract Research Organisation (CRO) Services Group, Clinquest Group, in a move that gives the company access to the fast-growing life sciences markets of Asia, in addition to its American and European presence.
Breast cancer therapeutics benefits from cytotoxic alternatives
The breast cancer therapeutics market is expected to show sustained growth and opportunity for new market participants as greater efficacy and reduced toxicity of innovative breast cancer therapies increase their uptake.
21-Dec-2005
Tripos streamlining includes slashing UK jobs
Tripos has announced the latest details in its cost cutting strategy, which is expected to result in job losses, principally in the UK. The cuts come as Tripo's four-year $90 million file enrichment project with Pfizer draws to a close.
ISO approves photometry for liquid volume measurement
Artel, has announced that the International Organisation for Standardisation (ISO) has approved the use of the photometric method for liquid delivery performance verification, which emphasises the role photometry has to play for drug discovery applications.
Cresset launches ion channel discovery tool
Cresset Biomolecular Discovery has launched a technology that identifies the 3-dimensional bound conformation of hits and potential drugs in a biological target, assisting scientists involved in ion channel research.
20-Dec-2005
DOV announces second Phase I trial for depression drug
DOV Pharmaceutical has announced the initiation of a Phase Ib clinical trial, which investigates the potential of its triple reuptake inhibitor candidate for treating depression. The drug's mechanism of action inhibits three separate neurotransmitters serotonin, norepinephrine and dopamine.
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): Round up.
The latest research included in the proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) means that antibiotic treatments and management therapies feature strongly in DrugResearcher’s round-up of the 4-day event.
15-Dec-2005
Accentia launches first chronic sinusitis test
The first diagnostic test available for the confirmation of chronic sinusitis (CS) disease has been made available by Accentia Biopharmaceuticals, which will assist in the identification of a problem that affects an estimated 31 million patients in the US
MiraiBio releases software for Luminex platform
MiraiBio has released software for the statistical analysis of multiplexed data generated on its liquid array detection system, a platform that is designed for immunoassay, enzyme function, and receptor-ligand interaction applications, all common in drug research and development.
La Jolla hails SSAO inhibitor potential
Latest data by La Jolla Pharmaceuticals indicate the potential of novel, orally active small molecule inhibitors of a central enzyme may provide clinical benefit for the treatment of stroke, ulcerative colitis, and other autoimmune diseases and inflammatory disorders.
IT outsourcing spending to grow in life sciences
According to a new report, it will become a necessity to outsource key activities related to securing and managing of data in the life sciences industry. This, coupled with the regulatory compliance, is driving the IT spending amongst the life science companies.
Roche enters diabetes drugs discovery collaboration
New insights into the dysregulation of beta cells and their impact on type 2 diabetes progression is now possible after Roche announced a partnership, which aims to identify novel pathways and new biomarkers for drug development.
13-Dec-2005
Solexa uses Genome Analyser to map human genome
Solexa has announced the introduction of its DNA sequencing, expression profiling and micro-RNA analysis platform designed to generate over a billion bases of sequence per run, making it ideal for plans to sequence the entire human genome in 2006.
Eye implants offer Parkinson's hope
A new therapy for Parkinson's disease involving brain implants has been developed by US scientists, who believe this new treatment is a viable alternative to drugs currently used to treat this chronic irreversible brain condition.
Thermo releases entry level crystallisation machine
Thermo Electron Corporation, have added to its crystallisation range with the new compact, entry-level, TableStore, which enhances protein structure and drug discovery investigations by offering optical clarity and automated storage capabilities within a small footprint.
CuraGen deal produces new cancer drug data
CuraGen and TopoTarget have announced preliminary data suggesting its small molecule candidate may have potential anti-tumour activity against haematologic cancer.
Eli Lilly offers positive 2006 outlook
US drug company, Eli Lilly, offered a more encouraging outlook than was expected forecasting an earnings growth of up to 12 per cent, a stark contrast to its struggling competitors, who also face generic competition, drug safety and regulation.
08-Dec-2005
Big Pharma ends difficult 2005 to face crunch year
According to a new report, 2006 will be a crunch year for companies that have expiring product patents looming. With generics increasingly penetrating the market, this has thrown into doubt the growth of this industry in the foreseeable future.
Clontech launches beads to TALON range
Clontech has announced a new addition to its TALON chemistry range, which uses magnetic bead technology to separate microscale quantities of protein when placed on a magnetic separator.
Phoqus' Phase I study heralds first Circadian drug
Phoqus has announced it has commenced Phase I of a clinical study researching its experimental treatment, which could become the first Circadian endocrine treatment for adrenal insufficiency.
GE's launch histidine-tagged protein spin columns
GE Healthcare has announced the availability of its single-use spin column designed for purification of histidine-tagged proteins using a standard microcentrifuge. It saves researchers time as it achieves direct protein purification in 10 minutes per run.
07-Dec-2005
Invitrogen broadens its biotech branches
Invitrogen has created three new business divisions in a move to strengthen its position in the growing biotechnology industry and drive growth through improving links between its product development cycle and customer base.
06-Dec-2005
Drug target molecule offers Down's hope
Researchers believe that they have identified a drug target molecule that could be used to treat mental impairment in people with Down's syndrome paving the way for a treatment that could improve the quality of life for sufferers.
Stratagene deal enters molecular diagnostics market
Stratagene announces a molecular diagnostics agreement, which aims to focus on the growing molecular diagnostics market for infectious diseases, currently worth $6.5 billion (€5.5 billion), expanding to $12 billion by 2010 driven biochip and nanobiotechnology developments.
New mechanisms explain cancer drug resistance
The question as to why some cancers resist drugs could be answered by the discovery of new mechanisms, which delve deeper into how cancer cells evolve to become resistant to various chemotherapy drugs.
BMS dAbs alliance promotes T-cell stimulation
Domantis has announced an alliance with pharma giants Bristol-Myers Squibb to develop human Domain Antibody (dAb) products, a novel approach to address therapeutic targets involved in T-cell co-stimulation.
Advaxis progress in dairy-based cancer vaccine
A dairy based vaccine could soon be on the horizon after researchers took a giant step in the development of a series of effective cancer-fighting vaccines that appear to be able to stop and reverse cancer growth.
05-Dec-2005
Emergent, CRO, in deal to develop Anthrax therapy
Clinical research organisation, Covalent Group, has agreed with Emergent BioSolutions to develop immune globulins for treatment exposure of anthrax infection, signifying another step in the worldwide drive to bring an effective treatment for this killer disease.
01-Dec-2005
Grants enable neuroprotective drug research
Researchers believe that new treatments or ways to diagnose memory problems will get a boost from a substantial grant that aims to create a brain-scanning method to test drug treatments, which investigates how brain cells age, and to develop neuroprotective drugs.
Roche and BioCryst collaborate on transplantation drug
Roche and BioCryst Pharmaceuticals announced an agreement to develop and commercialise BioCryst's phase I compound, which has been developed for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.
Oxford risks conflict as animal lab construction resumes
Oxford University has been given the go-ahead to resume building work on its new animal research laboratory complex, which had previously been the subject of protest from animal rights activists last summer.
Biopharmaceuticals emerging as preferred therapy, says report
A new report suggests that up to 30 biopharmaceutical products developed by UK companies using cell-based manufacturing techniques could be approved by 2012, reinforcing the idea that biopharmaceuticals are increasingly being seen as a viable alternative.
Gentra Systems launches pharmacogenomics kit
Gentra Systems has introduced its new versaGene DNA Cell Purification Kit, which responds to the growing need for high-quality DNA for sensitive downstream applications. The kit uses chemistry and column design to purify DNA with minimal RNA and protein contamination.
| « Previous month | Next month » |
© 2000/2009 - Decision News Media SAS - All right reserved.
